Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
© 2023. The Author(s)..
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Nature genetics - 55(2023), 5 vom: 12. Mai, Seite 807-819 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ravi, Arvind [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 20.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41588-023-01355-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355292548 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355292548 | ||
| 003 | DE-627 | ||
| 005 | 20240420232124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41588-023-01355-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM355292548 | ||
| 035 | |a (NLM)37024582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ravi, Arvind |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 700 | 1 | |a Hellmann, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Arniella, Monica B |e verfasserin |4 aut | |
| 700 | 1 | |a Holton, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Freeman, Samuel S |e verfasserin |4 aut | |
| 700 | 1 | |a Naranbhai, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Chip |e verfasserin |4 aut | |
| 700 | 1 | |a Leshchiner, Ignaty |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jaegil |e verfasserin |4 aut | |
| 700 | 1 | |a Akiyama, Yo |e verfasserin |4 aut | |
| 700 | 1 | |a Griffin, Aaron T |e verfasserin |4 aut | |
| 700 | 1 | |a Vokes, Natalie I |e verfasserin |4 aut | |
| 700 | 1 | |a Sakhi, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Kamesan, Vashine |e verfasserin |4 aut | |
| 700 | 1 | |a Rizvi, Hira |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciuti, Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Forde, Patrick M |e verfasserin |4 aut | |
| 700 | 1 | |a Anagnostou, Valsamo |e verfasserin |4 aut | |
| 700 | 1 | |a Riess, Jonathan W |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbons, Don L |e verfasserin |4 aut | |
| 700 | 1 | |a Pennell, Nathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Velcheti, Vamsidhar |e verfasserin |4 aut | |
| 700 | 1 | |a Digumarthy, Subba R |e verfasserin |4 aut | |
| 700 | 1 | |a Mino-Kenudson, Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Califano, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Heymach, John V |e verfasserin |4 aut | |
| 700 | 1 | |a Herbst, Roy S |e verfasserin |4 aut | |
| 700 | 1 | |a Brahmer, Julie R |e verfasserin |4 aut | |
| 700 | 1 | |a Schalper, Kurt A |e verfasserin |4 aut | |
| 700 | 1 | |a Velculescu, Victor E |e verfasserin |4 aut | |
| 700 | 1 | |a Henick, Brian S |e verfasserin |4 aut | |
| 700 | 1 | |a Rizvi, Naiyer |e verfasserin |4 aut | |
| 700 | 1 | |a Jänne, Pasi A |e verfasserin |4 aut | |
| 700 | 1 | |a Awad, Mark M |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Greenbaum, Benjamin D |e verfasserin |4 aut | |
| 700 | 1 | |a Luksza, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Alice T |e verfasserin |4 aut | |
| 700 | 1 | |a Wolchok, Jedd |e verfasserin |4 aut | |
| 700 | 1 | |a Hacohen, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Gad |e verfasserin |4 aut | |
| 700 | 1 | |a Gainor, Justin F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature genetics |d 1992 |g 55(2023), 5 vom: 12. Mai, Seite 807-819 |w (DE-627)NLM012651230 |x 1546-1718 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2023 |g number:5 |g day:12 |g month:05 |g pages:807-819 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41588-023-01355-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2023 |e 5 |b 12 |c 05 |h 807-819 | ||